The company ModernaTX, Inc is commencing the clinical of mRNA-1273 Vaccine in Adult Organ Transplant Recipients 

The condition is SARS-CoV-2. A new clinical trial is recruiting patients in the following locations: United States.

The trial officially began on the April 16, 2021 and is planned to complete on August 26, 2022.

This is an open-label study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1273 Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) vaccine in adults with a kidney or liver transplant and in healthy adult participants. The primary goal of the study is to evaluate the safety of mRNA-1273 and the serum antibody (Ab) responses obtained 28 days after the second dose of mRNA-1273.

The link to the complete study profile, the inclusion and exclusion criteria: https://ichgcp.net/clinical-trials-registry/NCT04860297.

Clinical Research News

Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products
Submission of comments on ICH E6 (R3) Guideline for Good Clinical Practice(GCP) - Step 2b 
ICH E6(R3) Good Clinical Practice guidance - Step 2 Public Consultation
The study of the new investigational drug for acute myeloid leukemia and myelodysplastic syndrome
Open Label study of entrectinib in ROS1 gene fusion-positive rare adult, paediatric and teenage/young adult cancers
Gasherbrum Bio, Inc is starting the study of GSBR-1290 drug in overweight or obese healthy adults
A new study of Dexpramipexole in adolescents and adults with severe Eosinophilic Asthma

Upcoming Clinical Trials

The company ModernaTX, Inc is commencing the clinical of mRNA-1273 Vaccine in Adult Organ Transplant Recipients 

All jobs

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe